Study on relationship between molecular subtypes of locally advanced breast cancer and neoadjuvant chemotherapy
10.3760/cma.j.issn.1674-6090.2010.05.004
- VernacularTitle:局部晚期乳腺癌分子亚型与新辅助化疗疗效关系的研究
- Author:
Yicong ZHANG
;
Benzhong WANG
;
Jingjie ZHANG
;
Min REN
;
Jing WANG
;
Jing PEI
;
Xiaojun XU
- Publication Type:Journal Article
- Keywords:
Breast cancer;
Neoadjuvant chemotherapy;
Molecular subtypes;
Predictive factors
- From:
Journal of Endocrine Surgery
2010;04(5):299-302,306
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the relationship between the four different molecular subtypes of locally advanced breast cancer(LABC) and the clinical effect of neoadjuvant chemotherapy containing docetaxel and anthracyclines on breast cancer. Methods The record of 68 patients with LABC who were treated with the therapeutic scheme was reviewed. Breast cancer molecules were diagnosed by core needle biopsy through IHC and were divided into four subtypes. After 3 to 5 courses of treatment, the relationship of molecular subtype and clinical effects was analyzed. Results Univariate analysis showed that absence of estrogen receptor (ER) expression and size of tumor (≤5cm) were predictive factors for clinical complete response (cCR) (P<0.05).Over expression of HER-2 and molecular subtypes were predictive for pathologic complete response (pCR) (P<0.05). pCR rate of HER2+/ER- subtype in this therapeutic scheme was, higher than that of other subtypes and pCR rate of Luminal A subtype was the lowest. Multivariate analysis showed that molecular subtypes cant be the predictive factors for this therapeutic scheme (P>0.05) and only HER-2 (P<0.05) was the independent variable in predicting pCR for this therapeutic scheme. Conclusion Molecular subtypes can not independently predict pCR for neoadjuvant chemotherapy regimen containing docetaxel and anthracyclines.
